Biologic Guidance And Oversight Develops More Specifics In Japan And Korea
This article was originally published in PharmAsia News
Executive Summary
The influx of biologic and biosimilar INDs is forcing Japan’s PMDA and Korea’s KFDA to reorganize their approval processes.